biote Corp Cash Flow Conversion Efficiency
biote Corp cash flow conversion efficiency. Based on the latest financial reports, biote Corp (BTMD) has a cash flow conversion efficiency ratio of -0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.90 Million) by net assets ($-47.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of biote Corp (2019–2025)
Cash flow conversion efficiency of biote Corp from 2019 to 2025. This chart illustrates how biote Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View biote Corp (BTMD) stock price for real-time trading data and today's change.
biote Corp Cash Flow Conversion Ratio Explained
biote Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
biote Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of biote Corp ranked by their cash flow conversion efficiency. Also see BTMD stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nyxoah
BR:NYXH
|
-0.402x |
|
Dabomb Protein
TWO:6578
|
0.000x |
|
Creas F&C Co.Ltd
KQ:110790
|
-0.010x |
|
CMR S.A.B. de C.V
MX:CMRB
|
0.393x |
|
Helixmith Co. Ltd
KQ:084990
|
-0.010x |
|
Hsinjing Holding Co Ltd
TWO:3713
|
0.028x |
|
Far East Fame Line DDB Public Company Limited
BK:FE
|
-0.010x |
|
Career Point Limited
NSE:CAREERP
|
0.004x |
Annual Cash Flow Conversion Efficiency for biote Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of biote Corp from 2019 to 2025. Review cash generation quality of biote Corp to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-50.40 Million | $35.19 Million | -0.698x | -57.75% |
| 2024-12-31 | $-102.20 Million | $45.24 Million | -0.443x | +39.82% |
| 2023-12-31 | $-36.55 Million | $26.88 Million | -0.736x | -568.12% |
| 2022-12-31 | $-58.27 Million | $-9.16 Million | 0.157x | -98.08% |
| 2021-12-31 | $4.12 Million | $33.72 Million | 8.175x | +628.21% |
| 2020-12-31 | $-17.07 Million | $26.43 Million | -1.548x | -100.99% |
| 2019-12-31 | $-32.93 Million | $25.35 Million | -0.770x | -- |
About biote Corp
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with … Read more